Circulating MicroRNA in inflammatory bowel disease.
ABSTRACT MicroRNAs (miRNAs) consist of a group of small noncoding RNAs that partially regulate gene expression. We investigated the expression patterns of commonly deregulated miRNAs in Crohn's disease (CD) and ulcerative colitis (UC) in peripheral blood samples of inflammatory bowel disease patients.
This study consisted of 128 CD and 88 UC patients, as well as 162 healthy controls. The expression patterns of the miRNA species were quantitatively assayed using reverse transcription and real-time RT-PCR. Stem-loop complementary DNAs (cDNAs) were synthesized using looped reverse transcription primers specific for each miRNA.
MiR-16, miR-23a, miR-29a, miR-106a, miR-107, miR-126, miR-191, miR-199a-5p, miR-200c, miR-362-3p and miR-532-3p were expressed at significantly higher levels in the blood from patients with CD compared with the healthy controls. No significant differences were observed when the CD patients were classified according to disease location and phenotype. In the UC cases three miRNAs (miR-16, miR-21, miR-28-5p, miR-151-5p, miR-155 and miR-199a-5p) were significantly increased compared to healthy controls. miR-155 was the most highly expressed of the UC-associated miRNA in blood samples.
Our results suggest that several miRNAs could distinguish CD from UC by real-time PCR. This further highlights the putative role of miRNAs as contributors to IBD pathogenesis. They may help develop new non-invasive biomarkers to distinguish UC and CD.
- [show abstract] [hide abstract]
ABSTRACT: The Brassica-derived isothiocyanate sulforaphane (SFN) is known to induce factor erythroid 2-related factor 2 (Nrf2), a transcription factor centrally involved in chemoprevention. Furthermore, SFN exhibits anti-inflammatory properties in vitro and in vivo. However, little is known regarding the anti-inflammatory properties of SFN in severe inflammatory phenotypes. In the present study, we tested if pre-treatment with SFN protects mice from dextran sodium sulphate (DSS)-induced colitis. C57BL/6 mice received either phosphate-buffered saline (control) or 25 mg/kg body weight (BW) SFN per os for 7 days. Subsequently, acute colitis was induced by administering 4% DSS via drinking water for 5 days and BWs, stool consistency and faecal blood loss were recorded. Following endoscopic colonoscopy, mice were sacrificed, the organs excised and spleen weights and colon lengths measured. For histopathological analysis, distal colon samples were fixed in 4% para-formaldehyde, sectioned and stained with hematoxylin/eosin. Inflammatory biomarkers were also measured in distal colon. Treatment with SFN prior to colitis induction significantly minimised both BW loss and the disease activity index compared to control mice. Furthermore, colon lengths in SFN pre-treated mice were significantly longer than in control mice. Both macroscopic and microscopic analysis of the colon revealed attenuated inflammation in SFN pre-treated animals. mRNA analysis of distal colon samples confirmed reduced expression of inflammatory markers and increased expression of Nrf2-dependent genes in SFN pre-treated mice. Our results indicate that pre-treating mice with SFN confers protection from DSS-induced colitis. These protective effects were corroborated macroscopically, microscopically and at the molecular level.The Journal of nutritional biochemistry 12/2013; 24(12):2085-2091. · 4.29 Impact Factor